APO Research
Talk to an analyst

APO RESEARCH · REPORT

KRAS Inhibitor

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

From a historical perspective KRAS inhibition represents the end of a four-decade “undruggable” saga. The RAS oncogenes HRAS and KRAS were among the first human cancer genes identified in the early 1980s, and activating RAS mutations are now known to drive roughly 20–30% of all human cancers, with KRAS the most frequently mutated isoform and almost universal in pancreatic ductal adenocarcinoma (PDAC). Despite intense medicinal-chemistry efforts, the small, smooth GTP-binding surface of KRAS was long thought to lack a druggable pocket. The field pivoted in 2013 when Shokat and colleagues described a previously unappreciated “switch II” allosteric pocket adjacent to the GTP-binding site that could be targeted by electrophilic fragments to form covalent adducts with cysteine at position 12 in KRAS G12C, opening the door to conformationally selective covalent inhibitors. This discovery set off an intense global race that, after nearly 40 years of negative experience, produced the first clinically successful KRAS-targeted drugs. Before 2021 there were no approved KRAS inhibitors and essentially no commercial revenue attributable to direct KRAS blockade; all treatment of KRAS-mutant tumors relied on cytotoxic regimens, immune checkpoint blockade, or pathway-level agents such as EGFR or MEK inhibitors.

Selected research

Market Outlook & Growth Opportunities

Global KRAS Inhibitor Market Outlook and Growth Opportunities 2026

25 December 2025196 pages

Choose your research edition.

Industry ResearchKRAS Inhibitor Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal KRAS Inhibitor Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal KRAS Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal KRAS Inhibitor Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal KRAS Inhibitor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

From a historical perspective KRAS inhibition represents the end of a four-decade “undruggable” saga. The RAS oncogenes HRAS and KRAS were among the first human cancer genes identified in the early 1980s, and activating RAS mutations are now known to drive roughly 20–30% of all human cancers, with KRAS the most frequently mutated isoform and almost universal in pancreatic ductal adenocarcinoma (PDAC). Despite intense medicinal-chemistry efforts, the small, smooth GTP-binding surface of KRAS was long thought to lack a druggable pocket. The field pivoted in 2013 when Shokat and colleagues described a previously unappreciated “switch II” allosteric pocket adjacent to the GTP-binding site that could be targeted by electrophilic fragments to form covalent adducts with cysteine at position 12 in KRAS G12C, opening the door to conformationally selective covalent inhibitors. This discovery set off an intense global race that, after nearly 40 years of negative experience, produced the first clinically successful KRAS-targeted drugs. Before 2021 there were no approved KRAS inhibitors and essentially no commercial revenue attributable to direct KRAS blockade; all treatment of KRAS-mutant tumors relied on cytotoxic regimens, immune checkpoint blockade, or pathway-level agents such as EGFR or MEK inhibitors.

The global KRAS inhibitor market is moving rapidly from an early-launch niche to a scaled targeted-oncology class. Based on APO Research’s estimates, global sales are expected to reach approximately US$0.49 billion in 2024 and grow to around US$3.18 billion by 2032, implying a strong CAGR of about 23–24% over 2025–2032. Growth is volume-driven rather than price-driven: worldwide demand is projected to increase from roughly 8.6 million to more than 78 million 120-mg-equivalent tablets over the same period, while global average net ex-factory prices gradually decline from the high-US$50s per tablet at launch to the low-US$40s by the early 2030s.

Read the full market overview

The market today is highly concentrated in a small number of tumour types and regions. Non-small-cell lung cancer (NSCLC) already accounts for the majority of KRAS inhibitor use, with colorectal cancer forming the second pillar and pancreatic plus other solid tumours contributing a small but fast-growing tail. North America remains the commercial centre of gravity, supported by high testing penetration, rapid reimbursement and comparatively high net prices. Europe scales later and at lower price points but still builds a meaningful second revenue pillar. Asia Pacific is the fastest-growing region: from a negligible base in 2021–2023, volumes expand sharply from 2024 onwards as Japan, South Korea, Australia and, critically, mainland China approve and commercialise KRAS G12C inhibitors. Because domestic products in China are priced materially below US and EU benchmarks, China’s late but rapid entry both reshapes the regional volume mix and pulls down Asia-Pacific average prices.

Competitive intensity is expected to increase as additional first-generation KRAS G12C inhibitors and next-generation molecules targeting other KRAS alleles enter the market. Amgen, Bristol Myers Squibb/Mirati, Innovent Biologics/GenFleet Therapeutics and Jacobio Pharma/Shanghai Allist Pharmaceuticals currently anchor the class, with other multinational and Chinese manufacturers developing follow-on assets. In 2024, the three largest vendors together account for well over 99% of global KRAS inhibitor revenue, but this concentration will moderate as new entrants launch, combination strategies proliferate and regional players consolidate positions in China and other emerging markets.

This report provides an overview of the global KRAS Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of KRAS Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents KRAS Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the KRAS Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

KRAS Inhibitor Segment by Company

Amgen

InventisBio/Chia Tai Tianqing Pharmaceutical

Bristol Myers Squibb/Mirati

Innovent Biologics/GenFleet Therapeutics

Jacobio Pharma/Shanghai Allist Pharmaceuticals

KRAS Inhibitor Segment by Type

Lung Cancer

Colorectal Cancer

Pancreatic Cancer

Others

KRAS Inhibitor Segment by Application

Clinic Laboratories

Hospitals

Cancer Diagnostic Centres

Others

KRAS Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global KRAS Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions KRAS Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify KRAS Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze KRAS Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KRAS Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of KRAS Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KRAS Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the KRAS Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global KRAS Inhibitor industry.

Chapter 3: Detailed analysis of KRAS Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of KRAS Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of KRAS Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. KRAS Inhibitor Industry Trends Table 2. KRAS Inhibitor Industry Drivers Table 3. KRAS Inhibitor Industry Opportunities and Challenges Table 4. KRAS Inhibitor Industry Restraints Table 5. Global KRAS Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global KRAS Inhibitor Revenue Share by Company (2021-2026) Table 7. Global KRAS Inhibitor Sales Volume by Company (k bottles) & (2021-2026) Table 8. Global KRAS Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global KRAS Inhibitor Average Price (USD/bottle) of Company (2021-2026) Table 10. Global KRAS Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global KRAS Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global KRAS Inhibitor Company, Product Type & Application Table 13. Global KRAS Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global KRAS Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lung Cancer Table 18. Significant Companies of Colorectal Cancer Table 19. Significant Companies of Pancreatic Cancer Table 20. Significant Companies of Others Table 21. Global KRAS Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (k bottles) Table 22. Global KRAS Inhibitor Sales Volume by Type (2021-2026) & (k bottles) Table 23. Global KRAS Inhibitor Sales Volume by Type (2027-2032) & (k bottles) Table 24. Global KRAS Inhibitor Sales Volume Share by Type (2021-2026) Table 25. Global KRAS Inhibitor Sales Volume Share by Type (2027-2032) Table 26. Global KRAS Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global KRAS Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global KRAS Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global KRAS Inhibitor Sales Value Share by Type (2021-2026) Table 30. Global KRAS Inhibitor Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Clinic Laboratories Table 32. Significant Companies of Hospitals Table 33. Significant Companies of Cancer Diagnostic Centres Table 34. Significant Companies of Others Table 35. Global KRAS Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (k bottles) Table 36. Global KRAS Inhibitor Sales Volume by Application (2021-2026) & (k bottles) Table 37. Global KRAS Inhibitor Sales Volume by Application (2027-2032) & (k bottles) Table 38. Global KRAS Inhibitor Sales Volume Share by Application (2021-2026) Table 39. Global KRAS Inhibitor Sales Volume Share by Application (2027-2032) Table 40. Global KRAS Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global KRAS Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global KRAS Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global KRAS Inhibitor Sales Value Share by Application (2021-2026) Table 44. Global KRAS Inhibitor Sales Value Share by Application (2027-2032) Table 45. Global KRAS Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k bottles) Table 46. Global KRAS Inhibitor Sales by Region (2021-2026) & (k bottles) Table 47. Global KRAS Inhibitor Sales Market Share by Region (2021-2026) Table 48. Global KRAS Inhibitor Sales by Region (2027-2032) & (k bottles) Table 49. Global KRAS Inhibitor Sales Market Share by Region (2027-2032) Table 50. Global KRAS Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global KRAS Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global KRAS Inhibitor Sales Value Share by Region (2021-2026) Table 53. Global KRAS Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global KRAS Inhibitor Sales Value Share by Region (2027-2032) Table 55. Global KRAS Inhibitor Market Average Price (USD/bottle) by Region (2021-2026) Table 56. Global KRAS Inhibitor Market Average Price (USD/bottle) by Region (2027-2032) Table 57. Global KRAS Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (k bottles) Table 58. Global KRAS Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 60. Global KRAS Inhibitor Sales Market Share by Country (2021-2026) Table 61. Global KRAS Inhibitor Sales by Country (2027-2032) & (k bottles) Table 62. Global KRAS Inhibitor Sales Market Share by Country (2027-2032) Table 63. Global KRAS Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global KRAS Inhibitor Sales Value Market Share by Country (2021-2026) Table 65. Global KRAS Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global KRAS Inhibitor Sales Value Market Share by Country (2027-2032) Table 67. Amgen Company Information Table 68. Amgen Business Overview Table 69. Amgen KRAS Inhibitor Sales (k bottles), Value (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 70. Amgen KRAS Inhibitor Product Portfolio Table 71. Amgen Recent Development Table 72. InventisBio/Chia Tai Tianqing Pharmaceutical Company Information Table 73. InventisBio/Chia Tai Tianqing Pharmaceutical Business Overview Table 74. InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Sales (k bottles), Value (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 75. InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Product Portfolio Table 76. InventisBio/Chia Tai Tianqing Pharmaceutical Recent Development Table 77. Bristol Myers Squibb/Mirati Company Information Table 78. Bristol Myers Squibb/Mirati Business Overview Table 79. Bristol Myers Squibb/Mirati KRAS Inhibitor Sales (k bottles), Value (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 80. Bristol Myers Squibb/Mirati KRAS Inhibitor Product Portfolio Table 81. Bristol Myers Squibb/Mirati Recent Development Table 82. Innovent Biologics/GenFleet Therapeutics Company Information Table 83. Innovent Biologics/GenFleet Therapeutics Business Overview Table 84. Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Sales (k bottles), Value (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 85. Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Product Portfolio Table 86. Innovent Biologics/GenFleet Therapeutics Recent Development Table 87. Jacobio Pharma/Shanghai Allist Pharmaceuticals Company Information Table 88. Jacobio Pharma/Shanghai Allist Pharmaceuticals Business Overview Table 89. Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Sales (k bottles), Value (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 90. Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Product Portfolio Table 91. Jacobio Pharma/Shanghai Allist Pharmaceuticals Recent Development Table 92. Key Raw Materials Table 93. Raw Materials Key Suppliers Table 94. KRAS Inhibitor Distributors List Table 95. KRAS Inhibitor Customers List Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. KRAS Inhibitor Product Image Figure 2. Global KRAS Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global KRAS Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global KRAS Inhibitor Sales (2021-2032) & (k bottles) Figure 5. Global KRAS Inhibitor Sales Average Price (USD/bottle) & (2021-2032) Figure 6. Global KRAS Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lung Cancer Image Figure 10. Colorectal Cancer Image Figure 11. Pancreatic Cancer Image Figure 12. Others Image Figure 13. Global KRAS Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (k bottles) Figure 14. Global KRAS Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global KRAS Inhibitor Sales Volume Share by Type (2021-2032) Figure 16. Global KRAS Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global KRAS Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global KRAS Inhibitor Sales Value Share by Type (2021-2032) Figure 19. Clinic Laboratories Image Figure 20. Hospitals Image Figure 21. Cancer Diagnostic Centres Image Figure 22. Others Image Figure 23. Global KRAS Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (k bottles) Figure 24. Global KRAS Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global KRAS Inhibitor Sales Volume Share by Application (2021-2032) Figure 26. Global KRAS Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global KRAS Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global KRAS Inhibitor Sales Value Share by Application (2021-2032) Figure 29. Global KRAS Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k bottles) Figure 30. Global KRAS Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global KRAS Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global KRAS Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America KRAS Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 34. North America KRAS Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe KRAS Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 36. Europe KRAS Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific KRAS Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific KRAS Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America KRAS Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 40. South America KRAS Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa KRAS Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa KRAS Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt KRAS Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. KRAS Inhibitor Value Chain Figure 128. Manufacturing Cost Structure Figure 129. KRAS Inhibitor Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Others
Applications
  • Clinic Laboratories
  • Hospitals
  • Cancer Diagnostic Centres
  • Others
Companies covered
  • Amgen
  • InventisBio/Chia Tai Tianqing Pharmaceutical
  • Bristol Myers Squibb/Mirati
  • Innovent Biologics/GenFleet Therapeutics
  • Jacobio Pharma/Shanghai Allist Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global KRAS Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global KRAS Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global KRAS Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 KRAS Inhibitor Market Dynamics
  1. 2.1 KRAS Inhibitor Industry Trends
  2. 2.2 KRAS Inhibitor Industry Drivers
  3. 2.3 KRAS Inhibitor Industry Opportunities and Challenges
  4. 2.4 KRAS Inhibitor Industry Restraints
3 KRAS Inhibitor Market by Company
  1. 3.1 Global KRAS Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global KRAS Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global KRAS Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global KRAS Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global KRAS Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global KRAS Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global KRAS Inhibitor Company Product Type and Application
  8. 3.8 Global KRAS Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global KRAS Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 KRAS Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 KRAS Inhibitor Market by Type
  1. 4.1 KRAS Inhibitor Type Introduction
  2. 4.1.1 Lung Cancer
  3. 4.1.2 Colorectal Cancer
  4. 4.1.3 Pancreatic Cancer
  5. 4.1.4 Others
  6. 4.2 Global KRAS Inhibitor Sales Volume by Type
  7. 4.2.1 Global KRAS Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global KRAS Inhibitor Sales Volume by Type (2021-2032)
  9. 4.2.3 Global KRAS Inhibitor Sales Volume Share by Type (2021-2032)
  10. 4.3 Global KRAS Inhibitor Sales Value by Type
  11. 4.3.1 Global KRAS Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global KRAS Inhibitor Sales Value by Type (2021-2032)
  13. 4.3.3 Global KRAS Inhibitor Sales Value Share by Type (2021-2032)
5 KRAS Inhibitor Market by Application
  1. 5.1 KRAS Inhibitor Application Introduction
  2. 5.1.1 Clinic Laboratories
  3. 5.1.2 Hospitals
  4. 5.1.3 Cancer Diagnostic Centres
  5. 5.1.4 Others
  6. 5.2 Global KRAS Inhibitor Sales Volume by Application
  7. 5.2.1 Global KRAS Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global KRAS Inhibitor Sales Volume by Application (2021-2032)
  9. 5.2.3 Global KRAS Inhibitor Sales Volume Share by Application (2021-2032)
  10. 5.3 Global KRAS Inhibitor Sales Value by Application
  11. 5.3.1 Global KRAS Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global KRAS Inhibitor Sales Value by Application (2021-2032)
  13. 5.3.3 Global KRAS Inhibitor Sales Value Share by Application (2021-2032)
6 KRAS Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global KRAS Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global KRAS Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global KRAS Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global KRAS Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global KRAS Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global KRAS Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global KRAS Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global KRAS Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global KRAS Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America KRAS Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America KRAS Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe KRAS Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe KRAS Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific KRAS Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific KRAS Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America KRAS Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America KRAS Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa KRAS Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa KRAS Inhibitor Sales Value Share by Country, 2025 VS 2032
7 KRAS Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global KRAS Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global KRAS Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global KRAS Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global KRAS Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global KRAS Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global KRAS Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global KRAS Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global KRAS Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt KRAS Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt KRAS Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt KRAS Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen KRAS Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Amgen KRAS Inhibitor Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 InventisBio/Chia Tai Tianqing Pharmaceutical
  8. 8.2.1 InventisBio/Chia Tai Tianqing Pharmaceutical Company Information
  9. 8.2.2 InventisBio/Chia Tai Tianqing Pharmaceutical Business Overview
  10. 8.2.3 InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Product Portfolio
  12. 8.2.5 InventisBio/Chia Tai Tianqing Pharmaceutical Recent Developments
  13. 8.3 Bristol Myers Squibb/Mirati
  14. 8.3.1 Bristol Myers Squibb/Mirati Company Information
  15. 8.3.2 Bristol Myers Squibb/Mirati Business Overview
  16. 8.3.3 Bristol Myers Squibb/Mirati KRAS Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bristol Myers Squibb/Mirati KRAS Inhibitor Product Portfolio
  18. 8.3.5 Bristol Myers Squibb/Mirati Recent Developments
  19. 8.4 Innovent Biologics/GenFleet Therapeutics
  20. 8.4.1 Innovent Biologics/GenFleet Therapeutics Company Information
  21. 8.4.2 Innovent Biologics/GenFleet Therapeutics Business Overview
  22. 8.4.3 Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Product Portfolio
  24. 8.4.5 Innovent Biologics/GenFleet Therapeutics Recent Developments
  25. 8.5 Jacobio Pharma/Shanghai Allist Pharmaceuticals
  26. 8.5.1 Jacobio Pharma/Shanghai Allist Pharmaceuticals Company Information
  27. 8.5.2 Jacobio Pharma/Shanghai Allist Pharmaceuticals Business Overview
  28. 8.5.3 Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Product Portfolio
  30. 8.5.5 Jacobio Pharma/Shanghai Allist Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 KRAS Inhibitor Value Chain Analysis
  2. 9.1.1 KRAS Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 KRAS Inhibitor Sales Mode & Process
  6. 9.2 KRAS Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 KRAS Inhibitor Distributors
  9. 9.2.3 KRAS Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst